Liminal BioSciences Inc. (LMNL)

NASDAQ: LMNL · IEX Real-Time Price · USD
0.451
0.000 (-0.04%)
Jun 24, 2022 10:03 AM EDT - Market closed
-0.04%
Market Cap 13.99M
Revenue (ttm) 343,651
Net Income (ttm) 17.31M
Shares Out 31.04M
EPS (ttm) 0.57
PE Ratio 0.79
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 54,363
Open 0.451
Previous Close 0.451
Day's Range 0.450 - 0.460
52-Week Range 0.365 - 4.180
Beta 1.54
Analysts Sell
Price Target 2.04 (+352.5%)
Earnings Date May 16, 2022

About LMNL

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein c... [Read more...]

Industry Biotechnology
CEO Kenneth Galbraith
Employees 251
Stock Exchange NASDAQ
Ticker Symbol LMNL
Full Company Profile

Financial Performance

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for LMNL stock is "Sell." The 12-month stock price forecast is 2.04, which is an increase of 352.53% from the latest price.

Price Target
$2.04
(352.53% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders

LAVAL, QC and CAMBRIDGE, England , June 6, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeti...

Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras

LAVAL, QC and CAMBRIDGE, England , May 23, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in ...

Liminal BioSciences Inc. (LMNL) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Liminal BioSciences Inc. (LMNL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions c...

Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple Ascendi...

Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022

LAVAL, QC and CAMBRIDGE, ENGLAND , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter ...

Liminal Biosciences to Present at Upcoming Investor Conferences

LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced tha...

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M secured loan...

Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras

Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose ("SAD...

Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

LAVAL, QC, and CAMBRIDGE, ENGLAND , March 7, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a wr...

Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP

Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1M Immediate termination of Loan Agreement and release of security interests over all of its secured ...

Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022

Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for ...

Liminal BioSciences Announces Strategic Priorities For 2022

LAVAL, QC and CAMBRIDGE, England, Jan. 19, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corpora...

Liminal BioSciences Reports Third Quarter 2021 Financial Results

Closing of the Sale of a Rare Pediatric Disease Priority Review Vou cher for gross proceeds of USD105M Closing of the Sale of the Remaining Plasma-Derived Therapeutics Business to Kedrion S.p.A Completi...

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

LAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the rem...

Liminal BioSciences Announces Closing of Sale of Priority Review Voucher

LAVAL, QC and CAMBRIDGE, England, Sept. 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeu...

After Plunging 34.5% in 4 Weeks, Here's Why the Trend Might Reverse for Liminal BioSciences Inc. (LMNL)

Liminal BioSciences Inc. (LMNL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni...

Liminal BioSciences Inc. (LMNL) Reports Q2 Loss, Misses Revenue Estimates

Liminal BioSciences Inc. (LMNL) delivered earnings and revenue surprises of 22.73% and -90.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Liminal BioSciences Reports Second Quarter 2021 Financial Results

Receipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Plasma-Derived Therapeutics Business to Kedri...

Liminal BioSciences Stock Is Trading Higher On Sale Of Priority Review Voucher For $105M

Liminal BioSciences Inc's (NASDAQ: LMNL) subsidiary Prometic Biotherapeutics Inc has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105M. The FDA granted the PRV with the a...

Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, its subsidiary Prometic Biotherapeu...

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility

LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced toda...

Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business w...

LAVAL, QC and CAMBRIDGE, England, June 23, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that, Kedrion S.p.A ("Kedrion") has exerc...

Liminal Announces Voting Results of Its 2021 Annual and Special General Meeting of Shareholders (AGM)

LAVAL, QC and CAMBRIDGE, England, June 4, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General and Sp...